NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT
Post# of 163

HeartBeam (NASDAQ: BEAT), a medical technology firm innovating in personalized cardiac care, has announced a strategic collaboration with AccurKardia, a leader in ECG-based diagnostics. The partnership will integrate AccurKardia’s FDA-cleared ECG analysis software, AccurECG™, into HeartBeam’s compact, cable-free 3D ECG device. Designed to deliver 12-lead ECGs remotely, the device will be enhanced by automated arrhythmia assessments, aiming to accelerate diagnosis and improve access to cardiac care. The collaboration is expected to streamline HeartBeam’s product development while expanding the reach of remote cardiac monitoring solutions.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://nnw.fm/BEAT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer

